Duopharma Biotech Stock

Equities

DPHARMA

MYL7148OO009

Pharmaceuticals

End-of-day quote BURSA MALAYSIA 06:00:00 2024-04-29 pm EDT 5-day change 1st Jan Change
1.18 MYR +0.85% Intraday chart for Duopharma Biotech +1.72% -6.35%
Sales 2024 * 772M 162M Sales 2025 * 829M 174M Capitalization 1.14B 239M
Net income 2024 * 83M 17.46M Net income 2025 * 96M 20.2M EV / Sales 2024 * 1.25 x
Net cash position 2024 * 166M 35.01M Net cash position 2025 * 163M 34.35M EV / Sales 2025 * 1.17 x
P/E ratio 2024 *
13.8 x
P/E ratio 2025 *
11.7 x
Employees -
Yield 2024 *
1.82%
Yield 2025 *
2.2%
Free-Float 45.25%
More Fundamentals * Assessed data
Dynamic Chart
Duopharma Biotech Clinches MYR578 million Supply Deals MT
Duopharma Biotech Berhad Announces the Appointment of Mohd Haris Bin Mohd Arshad as Non Independent and Non Executive Member of Nomination and Remuneration Committee CI
Duopharma Biotech Berhad Appoints Mohd Haris Bin Mohd Arshad as Non-Independent and Non-Executive Director CI
Duopharma Biotech Berhad Announces the Resignation of Amizar Binti Mizuar as Non Independent and Non Executive Member of Nomination and Remuneration Committee CI
Duopharma Biotech Berhad Announces the Resignation of Puan Amizar Binti Mizuar as Non Independent and Non Executive Director CI
Duopharma Biotech Berhad Announces the Cessation of Encik Muhammad Shukri Bin Ismail as Non Independent and Non Executive Alternate Director CI
Duopharma Biotech's Profit Plummets in Q4 2023 MT
Duopharma Biotech Berhad Reports Earnings Results for the Fourth Quarter and Full Year Ended December 31, 2023 CI
Duopharma Biotech Berhad Announces Second Interim Dividend in Respect of the Financial Year Ended 31 December 2023, Payable on 21 March 2024 CI
Duopharma Biotech Issues Further Islamic Debt Worth MYR29 Million MT
Duopharma Biotech Berhad Makes a Further Sukuk Wakalah Issuance of RMB 29.0 Million Under the Sukuk Wakalah Programme CI
Duopharma Biotech's Profit Drops in Q3 MT
Duopharma Biotech Berhad Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023 CI
Duopharma Biotech Bags Supply Deal Extension from Pharmaniga MT
Duopharma Biotech Berhad Declares Interim Dividend for the 30 June 2023, Payable on 22 September 2023 CI
More news
1 day+0.85%
1 week+1.72%
Current month-1.67%
1 month-1.67%
3 months-4.84%
6 months-1.67%
Current year-6.35%
More quotes
1 week
1.16
Extreme 1.16
1.21
1 month
1.14
Extreme 1.14
1.24
Current year
1.14
Extreme 1.14
1.33
1 year
1.11
Extreme 1.11
1.53
3 years
1.06
Extreme 1.06
2.70
5 years
0.79
Extreme 0.7875
3.29
10 years
0.61
Extreme 0.6107
3.29
More quotes
Managers TitleAgeSince
Chief Executive Officer 60 17-12-27
Director of Finance/CFO 59 00-08-06
Investor Relations Contact - -
Members of the board TitleAgeSince
Chairman 72 16-04-04
Chief Executive Officer 60 17-12-27
Director/Board Member 71 16-05-31
More insiders
Date Price Change Volume
24-05-02 1.26 +6.78% 6,183,200
24-04-30 1.18 +0.85% 159,500
24-04-29 1.17 -0.85% 284,000
24-04-26 1.18 -.--% 137,300
24-04-25 1.18 -0.84% 73,400

End-of-day quote BURSA MALAYSIA, April 29, 2024

More quotes
Duopharma Biotech Berhad is a Malaysia-based pharmaceutical company. The Company is engaged in the manufacturing and distribution of pharmaceutical products. Its business segments include Consumer Healthcare (CHC), Ethical Classic Business (ECB) and Ethical Specialty Business (ESB). The CHC is engaged in the manufacturing, marketing and distribution of over-the-counter products, such as vitamins and supplements, analgesics, eyecare and antacids to the domestic, regional and international markets. Its CHC brands include Flavettes, CHAMPS, Uphamol and Eye Glo. The ECB comprises more than 300 generic drugs manufactured by the Company, such as Crystorvas, Prelica and Omesec, among others. The ESB is focused on drugs for targeted conditions, as well as medical devices and consumables. It has also diversified into the biosimilars space with technology and commercialization collaborations with international partners. ERYSAA, Basalog One and Zuhera are a few commercialized biosimilar brands.
More about the company
Trading Rating
Investor Rating
ESG Refinitiv
B
More Ratings
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
4
Last Close Price
1.18 MYR
Average target price
1.475 MYR
Spread / Average Target
+25.00%
Consensus

Annual profits - Rate of surprise

  1. Stock Market
  2. Equities
  3. DPHARMA Stock